Holen Sie sich die Stockscreener-App
11.14
4.50%
0.48
Handel nachbörslich:
11.14
Schlusskurs vom Vortag:
$10.66
Offen:
$10.58
24-Stunden-Volumen:
193.37K
Relative Volume:
2.37
Marktkapitalisierung:
$956.06M
Einnahmen:
$106.66M
Nettoeinkommen (Verlust:
$15.16M
KGV:
-
EPS:
-
Netto-Cashflow:
$6.37M
1W Leistung:
+15.56%
1M Leistung:
-13.71%
6M Leistung:
+2.77%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.39
$11.14
1-Wochen-Bereich:
$9.67
$12.94
52-Wochen-Spanne:
$8.26
$27.10
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
(619) 949-3681
Adresse
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Vergleichen Sie GYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
11.14 | 956.06M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
Gyre therapeutics president Ma Songjiang sells $44,851 in stock By Investing.com - Investing.com Australia
Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock - MarketBeat
Gyre therapeutics president Ma Songjiang sells $44,851 in stock - Investing.com
Gyre Therapeutics (NASDAQ:GYRE) Shares Up 9.1%Time to Buy? - MarketBeat
Charles Schwab Investment Management Inc. Has $1.43 Million Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpHere's What Happened - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Increase in Short Interest - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Contrasting Gyre Therapeutics (NASDAQ:GYRE) and Bioxytran (OTCMKTS:BIXT) - Defense World
Short Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Declines By 16.1% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 7.8%Here's Why - MarketBeat
Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023) - Yahoo Finance
Gyre Therapeutics Reports Q3 2024 Financial Results and Strategic Updates - TipRanks
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides - The Bakersfield Californian
Gyre Therapeutics Revenue Falls 20% as Phase 3 Trial Milestone Nears Critical Data | GYRE Stock News - StockTitan
VirTra Appoints Retired U.S. Army Lieutenant General Maria R. Gervais and Georgia POST Executive Director Mike Ayers to Board of Directors - The Manila Times
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis - The Manila Times
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.8%What's Next? - MarketBeat
AQR Capital Management LLC Invests $778,000 in Mativ Holdings, Inc. (NYSE:MATV) - Defense World
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt - Yahoo Finance
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% - Defense World
Coronation Fund Managers Ltd. Buys 1,044 Shares of The Sherwin-Williams Company (NYSE:SHW) - Defense World
Eaton Vance California Municipal Income Trust (NYSE:CEV) Major Shareholder Sells $282,451.70 in Stock - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Trading 3.3% HigherHere's What Happened - MarketBeat
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference - The Manila Times
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Down 7.0% in August - MarketBeat
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday - Benzinga
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 4.9% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 6.6% - MarketBeat
Gyre Therapeutics Inc (GYRE) Stock Price & Chart | Trade Now - Capital.com
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 8.9% - MarketBeat
Short Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Grows By 5.4% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading 4.1% Higher - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 6.6% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Quotes, Forecast and News Summary - Benzinga
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Growth in Short Interest - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 8.2% - MarketBeat
Vanguard Group Inc. Reduces Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up to $10.40 - MarketBeat
GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024 - InvestorPlace
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 3.9% - MarketBeat
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - BioSpace
Sidoti Events, LLC's Virtual August Micro-Cap Conference - AccessWire
Gyre Therapeutics (NASDAQ:GYRE) Trading 6.7% Higher - MarketBeat
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference - ForexTV.com
Gyre Therapeutics Welcomes Dr. Epstein to Leadership Team - TipRanks
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - StockTitan
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gyre Therapeutics Inc-Aktie (GYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
Dec 17 '24 |
Sale |
11.05 |
2,000 |
22,109 |
2,940,467 |
| USMAN NASSIM | Director |
Jun 28 '24 |
Option Exercise |
6.93 |
3,452 |
23,922 |
5,088 |
| USMAN NASSIM | Director |
Jun 28 '24 |
Sale |
12.00 |
3,452 |
41,438 |
1,636 |
| USMAN NASSIM | Director |
May 01 '24 |
Option Exercise |
6.93 |
20,000 |
138,600 |
21,636 |
| USMAN NASSIM | Director |
May 01 '24 |
Sale |
14.13 |
20,000 |
282,577 |
1,636 |
| USMAN NASSIM | Director |
Apr 01 '24 |
Option Exercise |
6.93 |
20,000 |
138,600 |
21,636 |
| USMAN NASSIM | Director |
Apr 01 '24 |
Sale |
16.15 |
20,000 |
323,000 |
1,636 |
| USMAN NASSIM | Director |
Mar 15 '24 |
Option Exercise |
6.93 |
20,000 |
138,600 |
21,636 |
| USMAN NASSIM | Director |
Mar 15 '24 |
Sale |
17.26 |
20,000 |
345,200 |
1,636 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):